What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence indicates that Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) shows a moderate benefit over the standard treatment R-GemOx, with a statistically significant reduction in progression-free survival (HR 0.41, p=0.0001) and a non-significant but promising reduction in overall survival (HR 0.58, p=0.012) after the latest data cut. However, the overall survival results initially showed non-significant outcomes, which introduces some uncertainty.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for Glofit-GemOx are within the acceptable range for NHS resources, with the committee concluding that the ICERs are defensible. The analysis indicates that Glofit-GemOx provides good value for money, especially considering the uncertainties in the data.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document discusses the impact of diffuse large B-cell lymphoma on quality of life, it does not provide specific data on HRQoL improvements associated with Glofit-GemOx. The absence of validated HRQoL measures or significant improvements in patient-reported outcomes leads to a rating of minimal or mixed impact.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of Glofit-GemOx is reported to be very good, with mostly mild or moderate adverse events. The document indicates that serious adverse events are rare, supporting a strong tolerability rating.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against relevant standard-of-care options, specifically R-GemOx, which is widely used in the UK for the target population. The inclusion of Pola-BR as a comparator, despite its declining use, is justified due to its relevance in the treatment landscape.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is largely representative of the intended patient population, with subgroup analyses conducted. However, there are some concerns regarding the generalizability of the results to the NHS due to variability in regional outcomes.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Glofit-GemOx can be integrated into existing treatment pathways with minor adjustments. The committee noted that it fits well within the current clinical practice for patients who are not eligible for autologous stem cell transplant.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact analysis indicates that the resource implications of Glofit-GemOx are manageable and aligned with NHS planning. The committee concluded that the treatment is economically viable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a phase 3 RCT (STARGLO) with a reasonable sample size and follow-up. However, some methodological concerns and uncertainties regarding generalizability remain, which slightly lower the robustness rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the generalizability of the trial results to the NHS population and the indirect comparisons made. The committee acknowledged these uncertainties but noted that they could be mitigated by further analyses.
